Italy
· Delayed Price · Currency is EUR BridgeBio Pharma Statistics
Total Valuation
BIT:1BBIO has a market cap or net worth of EUR 12.31 billion. The enterprise value is 13.41 billion.
| Market Cap | 12.31B |
| Enterprise Value | 13.41B |
Important Dates
The next estimated earnings date is Wednesday, April 29, 2026.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 193.86M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.93% |
| Shares Change (QoQ) | +0.89% |
| Owned by Insiders (%) | 4.07% |
| Owned by Institutions (%) | 84.26% |
| Float | 160.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.80 |
| PB Ratio | -6.96 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -21.72 |
| EV / Sales | 31.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -35.22 |
Financial Position
The company has a current ratio of 2.77
| Current Ratio | 2.77 |
| Quick Ratio | 2.52 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.17 |
| Interest Coverage | -2.82 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -33.83% |
| Return on Invested Capital (ROIC) | -1,066.15% |
| Return on Capital Employed (ROCE) | -77.47% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 510,894 |
| Profits Per Employee | -737,663 |
| Employee Count | 839 |
| Asset Turnover | 0.54 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BIT:1BBIO has paid 370,490 in taxes.
| Income Tax | 370,490 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 61.31 |
| 200-Day Moving Average | 54.57 |
| Relative Strength Index (RSI) | 56.49 |
| Average Volume (20 Days) | 3 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 9.09 |
Income Statement
In the last 12 months, BIT:1BBIO had revenue of EUR 427.62 million and -617.42 million in losses. Loss per share was -3.22.
| Revenue | 427.62M |
| Gross Profit | 409.76M |
| Operating Income | -427.61M |
| Pretax Income | -623.87M |
| Net Income | -617.42M |
| EBITDA | -422.98M |
| EBIT | -427.61M |
| Loss Per Share | -3.22 |
Balance Sheet
The company has 500.36 million in cash and 1.59 billion in debt, giving a net cash position of -1.09 billion.
| Cash & Cash Equivalents | 500.36M |
| Total Debt | 1.59B |
| Net Cash | -1.09B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -1.77B |
| Book Value Per Share | -9.12 |
| Working Capital | 434.18M |
Cash Flow
In the last 12 months, operating cash flow was -379.78 million and capital expenditures -934,315, giving a free cash flow of -380.72 million.
| Operating Cash Flow | -379.78M |
| Capital Expenditures | -934,315 |
| Depreciation & Amortization | 4.64M |
| Net Borrowing | 355.23M |
| Free Cash Flow | -380.72M |
| FCF Per Share | n/a |
Margins
Gross margin is 95.82%, with operating and profit margins of -100.00% and -144.39%.
| Gross Margin | 95.82% |
| Operating Margin | -100.00% |
| Pretax Margin | -145.89% |
| Profit Margin | -144.39% |
| EBITDA Margin | -98.92% |
| EBIT Margin | -100.00% |
| FCF Margin | n/a |
Dividends & Yields
BIT:1BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.93% |
| Shareholder Yield | -2.93% |
| Earnings Yield | -5.01% |
| FCF Yield | -3.09% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BIT:1BBIO has an Altman Z-Score of -4.53 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.53 |
| Piotroski F-Score | 2 |